BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26661829)

  • 1. The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines.
    Zhao Z; Cai Q; Xu Y
    Lipids; 2016 Feb; 51(2):179-87. PubMed ID: 26661829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upregulation of IGF1 by tumor-associated macrophages promotes the proliferation and migration of epithelial ovarian cancer cells.
    Liu L; Wang X; Li X; Wu X; Tang M; Wang X
    Oncol Rep; 2018 Feb; 39(2):818-826. PubMed ID: 29251331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-215 functions as a tumor suppressor in epithelial ovarian cancer through regulation of the X-chromosome-linked inhibitor of apoptosis.
    Ge G; Zhang W; Niu L; Yan Y; Ren Y; Zou Y
    Oncol Rep; 2016 Mar; 35(3):1816-22. PubMed ID: 26676658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
    Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
    Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AEG -1 overexpression: a novel indicator for peritoneal dissemination and lymph node metastasis in epithelial ovarian cancers.
    Li C; Liu J; Lu R; Yu G; Wang X; Zhao Y; Song H; Lin P; Sun X; Yu X; Zhang Y; Ning X; Geng J
    Int J Gynecol Cancer; 2011 May; 21(4):602-8. PubMed ID: 21543927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor.
    Lungchukiet P; Sun Y; Kasiappan R; Quarni W; Nicosia SV; Zhang X; Bai W
    J Steroid Biochem Mol Biol; 2015 Apr; 148():138-47. PubMed ID: 25448740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
    Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
    Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Let-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.
    Xiao M; Cai J; Cai L; Jia J; Xie L; Zhu Y; Huang B; Jin D; Wang Z
    J Ovarian Res; 2017 Apr; 10(1):24. PubMed ID: 28376831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells.
    Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y
    Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo.
    Zhang L; Li Z; Gai F; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3107-14. PubMed ID: 25955305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific point mutations in key redox enzymes are associated with chemoresistance in epithelial ovarian cancer.
    Fletcher NM; Belotte J; Saed MG; Memaj I; Diamond MP; Morris RT; Saed GM
    Free Radic Biol Med; 2017 Jan; 102():122-132. PubMed ID: 27890641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of free fatty acid receptor 1 in EOC: A novel strategy to restrict the adipocyte-EOC dependence.
    Munkarah A; Mert I; Chhina J; Hamid S; Poisson L; Hensley-Alford S; Giri S; Rattan R
    Gynecol Oncol; 2016 Apr; 141(1):72-9. PubMed ID: 27016232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formyl peptide receptor 2 expression predicts poor prognosis and promotes invasion and metastasis in epithelial ovarian cancer.
    Xie X; Yang M; Ding Y; Yu L; Chen J
    Oncol Rep; 2017 Dec; 38(6):3297-3308. PubMed ID: 29039544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
    Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
    Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression.
    Deng J; Wang L; Chen H; Li L; Ma Y; Ni J; Li Y
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):535-51. PubMed ID: 23609751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.
    Lin M; Xia B; Qin L; Chen H; Lou G
    DNA Cell Biol; 2018 May; 37(5):491-500. PubMed ID: 29485916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct plasma lipids profiles of recurrent ovarian cancer by liquid chromatography-mass spectrometry.
    Li J; Xie H; Li A; Cheng J; Yang K; Wang J; Wang W; Zhang F; Li Z; Dhillon HS; Openkova MS; Zhou X; Li K; Hou Y
    Oncotarget; 2017 Jul; 8(29):46834-46845. PubMed ID: 27564116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.
    Qiu JJ; Lin YY; Ye LC; Ding JX; Feng WW; Jin HY; Zhang Y; Li Q; Hua KQ
    Gynecol Oncol; 2014 Jul; 134(1):121-8. PubMed ID: 24662839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.